creld2 Antibody

What is CRELD2 and why is it relevant to research?

CRELD2 (Cysteine-rich with EGF-like domains 2) is a member of the CRELD protein family that functions as both an endoplasmic reticulum (ER)-resident protein and a secretory factor. This protein is ubiquitously expressed across tissues at varying levels, suggesting diverse physiological roles . CRELD2 contains characteristic structural elements including:

• A signal peptide

• A highly conserved domain rich in glutamic acid and tryptophan (WE)

• EGF-like repeats

• A C-terminal (R/H)EDL sequence that regulates its secretion

Research interest in CRELD2 has grown due to its dramatic induction during ER stress and its implications in multiple pathological conditions including chronic liver diseases, cardiovascular diseases, kidney diseases, and cancer .

How is CRELD2 expression regulated during cellular stress?

CRELD2 expression is primarily regulated through ER stress pathways. Key regulatory mechanisms include:

• Transcriptional activation via ATF6 binding to the ER stress response element (ERSE; CGTGG-N9-ATTGG) in the CRELD2 promoter region

• Induction by chemical ER stress agents including thapsigargin (Tg), tunicamycin (Tm), and brefeldin A (BFA)

• Conservation of the ERSE motif across species, indicating evolutionary importance

Studies have demonstrated that ATF6 overexpression drastically induces CRELD2 mRNA expression through direct binding to the ERSE, while mutations in this element significantly decrease both basal activity and stress responsiveness .

What criteria should I consider when selecting a CRELD2 antibody for my research?

When selecting a CRELD2 antibody, consider these research-critical factors:

• Reactivity spectrum: Determine if the antibody recognizes human, mouse, or other species' CRELD2. For instance, mouse CRELD2 shares 77% amino acid sequence homology with human CRELD2 alpha isoform .

• Application compatibility: Verify antibody suitability for your specific applications. Common applications include:

• Epitope location: Consider whether the antibody targets full-length CRELD2 or specific regions that might be affected by post-translational modifications or isoform variations .

• Validation data: Review literature citations and validation data for the specific antibody to ensure reliable performance in your experimental system .

How can I validate a CRELD2 antibody for my specific experimental system?

Rigorous validation ensures experimental reliability. Follow these methodological steps:

• Positive control selection: Use tissues/cells known to express CRELD2 at detectable levels. For example, human placenta tissue, SH-SY5Y cells, and U2OS cells have been verified to express CRELD2 at levels detectable by western blot .

• Negative controls: Include samples with CRELD2 knockdown or from knockout models when available.

• Molecular weight verification: Confirm that the detected band corresponds to the expected molecular weight (calculated: 44 kDa; observed: 30-45 kDa range due to post-translational modifications) .

• Cross-reactivity assessment: Test for cross-reactivity with related proteins, particularly CRELD1, which shares structural features with CRELD2.

• Signal specificity: Implement peptide competition assays to confirm binding specificity to the CRELD2 epitope.

What are the optimal protocols for detecting CRELD2 using western blot?

For optimal western blot detection of CRELD2, follow these methodological recommendations:

• Sample preparation:

  • Lyse cells in buffer containing protease inhibitors to prevent degradation

  • Include phosphatase inhibitors if studying phosphorylation-dependent CRELD2 interactions

• Electrophoresis conditions:

  • Use 10-12% SDS-PAGE gels for optimal resolution

  • Load 20-30 μg of total protein per lane

• Transfer and blocking:

  • Transfer proteins to PVDF or nitrocellulose membranes

  • Block with 5% non-fat milk or BSA in TBST

• Antibody incubation:

  • Primary antibody: Use recommended dilution (typically 1:500-1:2000) in blocking buffer

  • Incubate overnight at 4°C with gentle agitation

  • Secondary antibody: HRP-conjugated anti-rabbit IgG (1:5000-1:10000)

• Detection specificities:

  • Expected molecular weight: Calculated 44 kDa

  • Observed range: 30-45 kDa (variation due to glycosylation)

• Controls:

  • Positive controls: Human placenta tissue, SH-SY5Y cells, U2OS cells

  • Loading control: β-actin or GAPDH

How should I optimize immunohistochemistry protocols for CRELD2 detection in tissue samples?

For successful IHC detection of CRELD2 in tissue samples:

• Tissue preparation:

  • Fix tissues in 10% neutral buffered formalin

  • Embed in paraffin and section at 4-6 μm thickness

• Antigen retrieval options:

  • Primary recommendation: TE buffer pH 9.0

  • Alternative: Citrate buffer pH 6.0

• Blocking and antibody incubation:

  • Block endogenous peroxidase with 3% H₂O₂

  • Block non-specific binding with 5-10% normal serum

  • Primary antibody dilution: 1:50-1:500 (optimize for your specific antibody)

  • Incubate at 4°C overnight or room temperature for 1-2 hours

• Detection system:

  • Use appropriate HRP-polymer detection system

  • Develop with DAB and counterstain with hematoxylin

• Positive tissue controls:

  • Human placenta tissue

  • Human pancreas tissue

• Expected results: CRELD2 typically shows cytoplasmic localization with concentration in the ER and Golgi regions.

How can I use CRELD2 antibodies to study ER stress pathways?

CRELD2 serves as an excellent marker for ER stress responses. Advanced experimental approaches include:

• Temporal analysis of CRELD2 induction:

  • Use time-course experiments with ER stress inducers (thapsigargin, tunicamycin)

  • Compare CRELD2 induction kinetics with other ER stress markers (BiP/GRP78, CHOP)

  • Western blot analysis can demonstrate the relative accumulation of CRELD2 within cells over time, which has been shown to peak at approximately one week in some models

• Co-localization studies:

  • Perform dual immunofluorescence with CRELD2 and other ER markers

  • Analyze subcellular localization changes during stress conditions

  • CRELD2 predominant localization has been confirmed in the ER and Golgi apparatus

• Secretion pathway analysis:

  • Monitor both intracellular and secreted CRELD2 levels during ER stress

  • Use dominant-negative COPII components (e.g., Sar1 mutants) to investigate secretion mechanism

  • Research has demonstrated that COPII-mediated transport from the ER to the Golgi apparatus is the main pathway for CRELD2 trafficking

• Promoter activity studies:

  • Use CRELD2 promoter-reporter constructs to monitor ATF6 activity

  • Mutational analysis of the ERSE element to assess contribution to stress response

What is the relationship between CRELD2 and calcium signaling, and how can it be studied?

Recent research has revealed intriguing connections between CRELD2 and calcium signaling:

• Calcium release assessment:

  • CRELD2 overexpression has been shown to impair calcium release from the ER, which affects calcineurin activation

  • Use calcium imaging techniques (Fura-2 AM) to measure intracellular calcium dynamics in cells with altered CRELD2 expression

• Mechanistic investigation:

  • Examine CRELD2 interactions with calcium channels and pumps using co-immunoprecipitation

  • Phosphoproteomic analysis can reveal CRELD2's impact on calcium-dependent signaling pathways

• Functional outcomes:

  • In osteoclasts, CRELD2 overexpression impairs differentiation by modulating calcium signaling

  • Similar mechanisms may exist in other cell types where calcium signaling is crucial

• Experimental approach:

  • Compare calcium dynamics in CRELD2 overexpressing versus knockdown cells

  • Assess downstream effects on calcineurin-NFAT signaling using reporter assays

  • Analyze cellular processes dependent on calcium (e.g., differentiation, secretion, motility)

Why might I observe multiple bands when detecting CRELD2 by western blot?

Multiple bands in CRELD2 western blots can result from several factors:

• Post-translational modifications:

  • Glycosylation heterogeneity: CRELD2 undergoes extensive glycosylation, resulting in observed molecular weights of 30-45 kDa despite a calculated mass of 44 kDa

  • Phosphorylation: CRELD2 may be differentially phosphorylated in response to cellular conditions

• Alternative splicing:

  • Up to 6 different isoforms have been reported for human CRELD2

  • Verify which isoforms your antibody recognizes and their expected sizes

• Proteolytic processing:

  • Signal peptide cleavage and other processing events can generate fragments

  • Include protease inhibitors in sample preparation

• Experimental approach to resolve this issue:

  • Use glycosidase treatment to remove N-linked glycans and simplify banding pattern

  • Compare bands from multiple antibodies targeting different CRELD2 epitopes

  • Include positive controls with known CRELD2 expression patterns

How can I differentiate between intracellular and secreted CRELD2 in my experimental system?

Distinguishing intracellular from secreted CRELD2 requires specific experimental approaches:

• Compartmental analysis:

  • Collect both cell lysates and conditioned media separately

  • Concentrate secreted proteins from media using TCA precipitation or centrifugal filters

  • Western blot analysis of both fractions with appropriate controls

• Secretion kinetics:

  • Time-course experiments to track the appearance of CRELD2 in culture media

  • Pulse-chase labeling to follow newly synthesized CRELD2 through secretory pathway

• C-terminal modifications:

  • The secretion of CRELD2 is regulated by its C-terminal (R/H)EDL sequence

  • Mutations in this region can drastically enhance CRELD2 secretion

  • Consider using CRELD2 constructs with modified C-termini as controls

• KDELR competition analysis:

  • Co-expression studies with GRP78 can enhance CRELD2 secretion through competition for KDEL receptors

  • During ER stress, upregulation of multiple proteins with ER retention motifs (like GRP78) may competitively displace CRELD2 from KDELRs, increasing its secretion

How can CRELD2 antibodies be used to investigate ER stress in disease pathogenesis?

CRELD2 antibodies offer valuable tools for studying ER stress contributions to disease:

• Tissue-specific ER stress analysis:

  • IHC analysis of CRELD2 in disease tissue samples can serve as a marker of ER stress

  • Compare CRELD2 expression patterns in healthy versus pathological tissues

  • CRELD2 has been investigated in chronic liver diseases, cardiovascular diseases, kidney diseases, and cancer

• Disease progression markers:

  • Monitor CRELD2 levels in serum/plasma as potential biomarkers for ER stress-related pathologies

  • Correlate CRELD2 expression with disease severity and progression

• Therapeutic intervention assessment:

  • Use CRELD2 antibodies to evaluate the efficacy of ER stress-targeting therapies

  • A CRELD2-neutralizing antibody approach has been tested to assess the importance of secreted CRELD2 in myocardial infarction models

• Cell-type specific responses:

  • Dual staining with cell type markers and CRELD2 antibodies can reveal which cells experience ER stress in complex tissues

  • In cartilage disorders, for example, CRELD2 accumulation has been observed specifically in chondrocytes

What is known about CRELD2's role in skeletal disorders, and how can it be further investigated?

CRELD2 has emerging roles in skeletal biology that can be investigated using specific approaches:

• Current knowledge:

  • CRELD2 is upregulated in models of multiple epiphyseal dysplasia (MED)

  • CRELD2 expression decreases during osteoclast differentiation, suggesting an inhibitory role

  • Overexpression of CRELD2 impairs osteoclast differentiation and resorptive activity

• Mechanistic studies:

  • CRELD2 interacts with mutant matrilin-3 (V194D) but not with COMP, indicating substrate specificity

  • CRELD2 has PDI-like activity, suggesting a role in protein folding and quality control

  • CRELD2 overexpression impairs calcium release from the ER, which is essential for calcineurin activation in osteoclasts

• Experimental approaches:

  • Generate cell-specific CRELD2 knockout or overexpression models in osteoblasts and osteoclasts

  • Perform transcriptomic analyses to identify downstream targets affected by CRELD2 modulation

  • Use co-immunoprecipitation with CRELD2 antibodies to identify novel interaction partners in bone cells

  • Analyze CRELD2 in patient samples with various skeletal dysplasias

• Potential therapeutic applications:

  • Target CRELD2 interactions to alleviate ER stress in skeletal disorders

  • Modulate CRELD2 levels to influence osteoclast differentiation in bone disorders with excessive resorption

What are emerging techniques for studying CRELD2 protein-protein interactions?

Advanced techniques to investigate CRELD2's interactome include:

• Proximity labeling approaches:

  • BioID or APEX2 fusion with CRELD2 to identify proximal proteins in living cells

  • TurboID for rapid labeling of transient interactions in the secretory pathway

• Structural biology techniques:

  • Cryo-EM analysis of CRELD2 complexes with interaction partners

  • Hydrogen-deuterium exchange mass spectrometry to map interaction interfaces

• High-throughput screening:

  • CRISPR activation/interference screens to identify genes affecting CRELD2 expression or secretion

  • Small molecule screens for compounds that modulate CRELD2 function or secretion

• Targeted proteomic approaches:

  • Phosphoproteomics to identify downstream signaling targets of CRELD2, similar to studies that identified CRELD2 activation of AMPK and AKT pathways

  • Glycoproteomics to characterize CRELD2 post-translational modifications

How can single-cell technologies advance our understanding of CRELD2 in heterogeneous tissues?

Single-cell approaches offer unprecedented insights into CRELD2 biology:

• Single-cell transcriptomics:

  • Map CRELD2 expression patterns across cell types in normal and stressed tissues

  • Identify co-regulated gene networks associated with CRELD2 expression

• Single-cell proteomics:

  • Quantify CRELD2 protein levels at single-cell resolution

  • Correlate with other ER stress markers to identify cellular subpopulations with active UPR

• Spatial transcriptomics/proteomics:

  • Analyze CRELD2 expression in the spatial context of tissues

  • Identify localized ER stress responses in specific tissue microenvironments

• Multimodal analysis integration:

  • Combine CRELD2 antibody-based detection with transcriptomic or epigenomic profiling

  • Develop computational approaches to integrate multiple data types for comprehensive understanding of CRELD2's role in tissue homeostasis and disease